EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies

Blake Foxworthy, Chen Dai, Elizabeth C Davis, Ana C Xavier, Julienne Brackett, David Dickens iD, Alissa Kahn, Isaac Martinez, Archana Sharma iD, Carla Schwalm, Jessica Foley, Jennifer Wilkes iD und 5 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31082 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Blake Foxworthy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms, Down Syndrome, SARS-CoV-2. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Concern Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Children, adolescents, and young adults (CAYAs) with Down syndrome (DS) and hematologic malignancies are particularly vulnerable to infections and related complications. There are limited data regarding COVID‐19 infections in this group. We aimed to understand the clinical course of COVID‐19 in this population.

Methods

This observational study leverages the de‐identified clinical and sociodemographic data captured by the Pediatric Oncology COVID‐19 Case Report Registry (POCC) regarding CAYAs with cancer and COVID‐19. We evaluated CAYAs (≤21 years at COVID‐19 infection) with hematologic malignancies and COVID‐19 reported from April 1, 2020 to May 2, 2023, comparing those with and without DS. Using multivariable logistic regression, we examined rates of hospitalization, intensive care unit (ICU) admission, respiratory support, and changes in cancer‐directed therapy.

Results

Among 1408 CAYAs with hematologic malignancies, 55 had DS (CAYA‐DS). CAYA‐DS had higher rates of hospitalization, ICU admission, and respiratory support ( p < .001) than CAYAs without DS. Similarly, multivariable analyses found higher odds of hospitalization (odds ratio [OR] = 2.8, 95% confidence interval [CI]: 1.5–5.1), ICU admission (OR = 4.2, 95% CI: 1.9–9.1), and need for respiratory support (OR = 4.2, 95% CI: 2.0–8.8) among CAYA‐DS. Modifications to cancer‐directed therapy were more common among CAYA‐DS when related to neutropenia ( p = .001), but not when unrelated to neutropenia ( p = .88); CAYA‐DS did not have higher odds of changes to cancer‐directed therapy (OR = 1.20, 95% CI: 0.7–2.1).

Conclusions

We identify CAYA‐DS with hematologic malignancies as a vulnerable subpopulation at greater risk for severe COVID‐19 infection. This can inform conversations with patients and families regarding therapeutic and preventive measures, as well as the risks and benefits of modifying chemotherapy in the setting of COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsDown SyndromeSARS-CoV-2HospitalizationHumansAdolescentMaleFemaleChildYoung AdultAdultChild, PreschoolInfant

Stichwörter der Autor:innen

COVIDDown syndromecancerhematologic malignancyleukemia

Autor:innen und Institutionen

  • Pediatric Hematology-Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Department of Surgery, Boston University, Boston, USA.
  • Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Pediatric Hematology-Oncology, Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
  • Pediatric Hematology-Oncology, Department of Pediatrics, Saint Joseph's University Medical Center, Paterson, New Jersey, USA.
  • Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: David Dickens, Archana Sharma, Jennifer Wilkes, Emily E Johnston, Julie A Wolfson

Förderung

  • Concern Foundation

Zitieren

APA

Foxworthy, B., Dai, C., Davis, E. C., Xavier, A. C., Brackett, J., Dickens, D., Kahn, A., Martinez, I., Sharma, A., Schwalm, C., Foley, J., Wilkes, J., POCC Consortium, Bhatia, S., Levine, J. M., Johnston, E. E., & Wolfson, J. A. (2024). COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31082

Vancouver

Foxworthy B, Dai C, Davis EC, Xavier AC, Brackett J, Dickens D, et al. COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31082

BibTeX
@article{Foxworthy2024,
  author = {Foxworthy, Blake and Dai, Chen and Davis, Elizabeth C and Xavier, Ana C and Brackett, Julienne and Dickens, David and Kahn, Alissa and Martinez, Isaac and Sharma, Archana and Schwalm, Carla and Foley, Jessica and Wilkes, Jennifer and POCC Consortium, POCC Consortium and Bhatia, Smita and Levine, Jennifer M and Johnston, Emily E and Wolfson, Julie A},
  title = {COVID‐19 infection in children, adolescents, and young adults with Down syndrome and hematologic malignancies},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31082}
}
Kostenlos starten →